Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning by Boga, C. et al.
Hematol Oncol Stem Cell Ther (2018) 11, 149–157Avai lab le a t www.sc ienced i rec t .com
ScienceDirect
journal homepage: www.elsev ier .com/ locate /hemoncORIGINAL RESEARCH REPORTEffects of two doses of anti-T lymphocyte
globulin-Fresenius given after full-match
sibling stem cell transplantation in acute
myeloblastic leukemia patients who
underwent myeloablative fludarabine/
busulfan conditioninghttps://doi.org/10.1016/j.hemonc.2018.01.004
1658-3876/ 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author at: Department of Hematology, Faculty of Medicine, Baskent University, Yuregir 01250, Adana, Turkey
E-mail address: drcanboga@hotmail.com (C. Boga).
Downloaded for Anonymous User (n/a) at Baskent University from ClinicalKey.com by Elsevier on June 28, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.Can Boga a,*, Mahmut Yeral a, Cig˘dem Gereklioglu b, Suheyl Asma b,
Erkan Maytalman a, Pelin Aytan a, Ilknur Kozanoglu a,c, Cagla Sariturk d,
Hakan Ozdogu aaHematology Department, Adana Adult BMT Center, Faculty of Medicine, Baskent University, Ankara, Turkey
b Family Medicine Department, Faculty of Medicine, Baskent University, Ankara, Turkey
c Physiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
dMedical Statistics, Adana Hospital, Baskent University, Adana, TurkeyReceived 13 March 2017; received in revised form 18 October 2017; accepted 21 January 2018
Available online 20 February 2018KEYWORDS
Acute myeloblastic
leukemia;
Allogeneic stem cell
transplantation;
Anti-T lymphocyte globulin;
Antithymocyte globulin;
Graft-versus-host diseaseAbstract
Objective/background: Anti-T lymphocyte globulin Fresenius (rATG-F; ATG-Fresenius) and
antithymocyte globulin (thymoglobulin), which are included in transplant protocols, are used
to reduce the risk of chronic graft-versus-host disease (cGVHD) or suppress allograft rejection.
Available clinical studies have been conducted in heterogenous patient populations and with
different administration protocols including stem cell sources. Additionally, the pharmacoki-
netics of ATG is variable, and the clinically effective dose of rATG-F, in particular, is not
exactly known. The aim of the study was to investigate the clinical outcomes of acute myeloid
leukemia (AML) patients who underwent hemopoietic peripheral stem cell transplantation from
full-matched sibling donors and given two different doses of r-ATG-F..
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For personal useMethods: This was a single-center, retrospective chart review conducted between July 2005
and July 2016. Sixty-nine consecutive AML patients who underwent transplant with
fludarabine- and busulfan-based conditioning were included in the study. Patients in Group 1
received 15 mg/kg body weight rATG-F to 2013 (n = 46), and Group 2 received 30 mg/kg of
rATG-F dose begining in 2013 to reduce to cGVHD (n = 23). Cyclosporine and methotrexate were
used to treat acute GVHD (aGVHD) prophylaxis. Outcome parameters were compared between
the groups.
Results: Although the recommended dose r-ATG-F had led to a decrease in the cumulative inci-
dence of cGVHD (27 [58.7%] vs. 8 [34.8%]; p = .03), it also increased the infection rate at 1 year
(3 [6.5%] vs. 4 [17.4%]; p = .02). The two groups were similar in terms of engraftment time,
aGVHD, relapse, nonrelapse mortality, and rATG-F-related toxicity. A Cox regression model
revealed that aGVHD III–IV was associated with increased nonrelapse mortality at 1 year (haz-
ard ratio = 18.2; 95% confidence interval, 1.667–199.255; p = <.02). No patients developed
rATG-F-related severe adverse events (Common Terminology Criteria grade 4 or 5).
Conclusion: Dose difference of rATG-F did not influence survival parameters; however,
increasing the dose to 30 mg/kg seems to be effective for reducing cGVHD with an increase
in infection rate requiring close monitoring of infections in AML patients who received myeloab-
lative fludarabine/busulfan conditioning.
 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Anti-T lymphocyte globulin (rATG-F; ATG-Fresenius) is a
preparation of rabbit polyclonal antibodies against the Jur-
kat T lymphoblastocytoid cell line [1,2]. Antithymocyte
globulin (thymoglobulin) is prepared using more heteroge-
neous human thymus cells as antigens [1,2]. Both antibody
preparations trigger complement-mediated lysis and apop-
tosis of blood and lymph node cells, and also control the
leukocyte/endothelium relationship, increase B-cell apop-
tosis, regulate dendritic cell functions, and induce T-
regulatory cells and natural killer T cells. These effects
are associated with antibody-binding to many membrane
surface antigens [1–3]. The antibodies of rATG-F are less
diverse than those of thymoglobulin; this reflects the man-
ufacturing approach taken. For example, rATG-F does not
bind to CD4 or HLA-DR [1–3]. The antibodies reduce the risk
of chronic graft-versus-host disease (cGVHD) or suppress
allograft rejection when administered in allogeneic
hematopoietic stem cell transplantation (HSCT) protocols
[4–7]. Most of the available in vitro and clinical data are
derived from studies performed using Thymoglobulin [1,8–
10]. Optimization of dosing is necessary to determine the
clinically effective dose of rATG-F. However, it is challeng-
ing work because of the highly variable pharmacokinetics of
the drugs and likelihood of increased cGVHD risk attributa-
ble to reduced dose thymoglobulin [1,2,9]. In the literature,
the patient populations were not homogenous: different
conditioning regimens including different stem cell sources
were used, follow-up was not standardized, and the clini-
cally effective doses of rATG-F were not clear; these issues
require attention [4–11]. Therefore, we decided to conduct
our study in a homogenous patient group using a standard
protocol and follow-up.
The clinical outcomes of acute myeloid leukemia (AML)
patients given two different doses of rATG-F and who under-
went HSCT using peripheral stem cells from full-matchedonymous User (n/a) at Baskent University
 only. No other uses without permission. Csibling donors with myeloablative busulfan/fludarabine-
based conditioning regimens were investigated in the pre-
sent study.
Materials and methods
Study design
This was a single-center, retrospective chart review con-
ducted between July 2005 and July 2016. A total of 69 con-
secutive primary or treatment-related AML patients who
were older than 18 years, in remission, and who underwent
peripheral stem cells transfer from HLA full-matched donors
were included. Group 1 was composed of 46 patients who
received reduced-dose rATG-F to 2013, and Group 2 had
23 patients who received the recommended rATG-F dose
beginning in 2013. The conditioning regimens featured 15
mg/kg of rATG-F (Grafalon; Fresenius, Bad Homburg,
Germany) for Group 1 and 30 mg/kg of rATG-F (Grafalon)
for Group 2, given over the final 3 days prior to donor cell
infusion, in combination with 150 mg/kg of fludarabine
and 9.6–12.8 mg/kg of busulfan. Cyclosporine and
methotrexate were used to treat acute GVHD (aGVHD)
prophylaxis.
Data were obtained from forms created to evaluate trans-
plant patients. The forms met the Joint Accreditation Com-
mittee: International Society for Cellular Therapy and the
EuropeanGroup for Blood andMarrowTransplantation (JACIE)
Accreditation criteria for theNucleus electronicdatamanage-
ment system (version 9.3.39; Monad Software Co., Ankara,
Turkey). All data were checked by a Data Audit Group.
The primary endpoints included probabilities of overall
survival (OS) and disease-free survival (DFS), and the cumu-
lative incidences of relapse, nonrelapse mortality (NRM),
and cGVHD. The secondary endpoints included the cumula-
tive incidence of aGVHD, infection rate, and proportion of
patients for whom immunosuppressive drugs could be dis- from ClinicalKey.com by Elsevier on June 28, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Effects of two doses of ATG-Fresenius 151continued by Year 2. For patients aged 18 years and below,
and those with another cancer or who received unrelated or
HLA-unmatched transplants, a second transplant were
excluded.
Local Ethics Committee approval was obtained prior to
study commencement (KA16/284).
Stem cell collection
All donors were given 10 lg/kg/day filgrastim (Neupogen;
Amgen-Roche, Thousand Oaks, CA, USA) in two equal doses
for 5 days prior to peripheral stem cell collection, with the
aim of mobilizing stem cells from the bone marrow into
peripheral blood. An apheresis device using a continuous
flow technique (Cobe Spectra V. 7.0; Terumo BCT, Lake-
wood, CO, USA) was used to collect stem cells.
Transplantation procedure
All patients received an ablative conditioning regimen (9.6–
12.8 mg/kg busulfan via intravenous route, 150 mg/kg flu-
darabine). In addition, Group 1 cases received 15 mg/kg
rabbit ATG (Grafalon, Fresenius, Germany) and Group 2
cases received higher doses of rabbit ATG (30 mg/kg) with
the aim of reducing cGVHD rates. For aGVHD prophylaxis,
all patients received cyclosporine (3 mg/kg/day intra-
venously beginning at Day–2; the target concentration
was 200 ng/mL to the time of drug discontinuation) and
methotrexate (10 mg/m2 intravenously on Day 2; 8 mg/m2
intravenously on Days 4 and 8); folinic acid was given 24 h
after each dose of methotrexate. Acute GVHD was scored
using the standard criteria based on the pattern of severity
of abnormalities in the skin, gastrointestinal tract, and liver
[12]. The initial dose of methylprednisolone was 2 mg/kg
when GVHD developed. cGVHD was diagnosed according to
standardized criteria [13]. All patients were followed up in
rooms with a laminar airflow. Irradiated, leukocyte-free
blood products were used when transfusions were needed.
The threshold hemoglobin level was <8 g/L for administra-
tion of an erythrocyte suspension, and the threshold plate-
let level was <20  109/L for administration of concentrated
platelets. All workflow during chemotherapy, and antimi-
crobial drug use, were conducted in accordance with stan-
dard operating procedures (SOPs) prepared prior to JACIE
accreditation (SOP of bone marrow transplantation clinical
unit: BMT-CU 032). All patients received acyclovir for herpes
prophylaxis, sulfamethoxazole for Pneumocystis jiroveci
prophylaxis, and empirical cephalosporin–clavulonate and
carbapenem until microbiological data were obtained if feb-
rile neutropenia was evident; glycopeptides were given
when Gram-positive bacterial infection was suspected. Viral
and antifungal prophylaxis was delivered in accordance with
SOPs prepared prior to JACIE accreditation (SOP: BMT-CU
002). Preemptive ganciclovir was given in patients exhibit-
ing cytomegalovirus reactivation.
Minimal residual disease analysis
All flow cytometry measurements were performed using the
blue (wavelength = 488 mm) and red (wavelength = 633 mm)
lasers of an eight-parameter Becton Dickinson FACS CANTODownloaded for Anonymous User (n/a) at Baskent Univers
For personal use only. No other uses without permissionII device (BD Bioscience, San Jose, CA, USA). Leukemia-
related immune typing was performed at the time of diag-
nosis. Three tubes containing diagnostic markers of AML
(CD45APC H7, CD13 APC, CD33 PerCp, CD7 PE, CD19
AlexaFluor, CD56 PE, CD123 PerCp, CD34 PE-Cy7, CD11b
Alexa Fluor, HLA DR APC, CD38 FITC, CD15 FITC, CD64 PE,
and CD14 Alexa Fluor) were used. Each tube received
approximately 106 cells, which were evaluated using FACS
DIVA Software (BD Bioscience). Minimal residual disease
(MRD) was defined as the presence of cell groups exhibiting
abnormal antigen expression during maturation of bone
marrow cell lines. If possible, the same monoclonal antibod-
ies and fluorochromes were used for MRD follow-up after
diagnosis. The MRD bone marrow-positive cutoff was 0.1%.
All antibodies were supplied by BD Bioscience.
Response criteria
Normalization of cell counts in the peripheral blood,
absence of abnormal blasts in the peripheral blood, and a
bone marrow blast count 5% were the full response crite-
ria. As an institution standard, bone marrow aspiration was
performed every 2–4 months until 2 years after transplanta-
tion and whenever needed thereafter. Toxicities were
determined using the criteria of the National Cancer
Institute.
Statistics
A comparison was made between HLA-matched sibling
donor transplants using reduced dose rATG-F (Group 1)
and recommended dose rATG-F (Group 2) in the allo-HSCT
cohort including AML patients. Baseline categorical vari-
ables were compared using Fisher’s exact test, whereas
continuous variables were compared using Mann–Whitney
U test or two-sample t test as appropriate. OS and DFS were
estimated using the Kaplan–Meier method. OS was defined
as the time from transplant to death, and surviving patients
were censored at last follow-up. DFS was defined as the
time from transplantation to disease relapse and/or death.
Probabilities of DFS and OS were calculated as described
previously [14]. OS and DFS data were analyzed using the
log-rank test. NRM was defined as death from any cause
other than disease progression or relapse. Cumulative inci-
dences of NRM and relapse were calculated with relapse
or death as a competing event, respectively [15]. Compar-
isons between estimates of cumulative incidences were
made by using Gray’s test. The cumulative incidence of
aGVHD or cGVHD was calculated with relapse or death with-
out relapse or GVHD as a competing event for both [16]. Cox
proportional hazards models were constructed for a cumula-
tive incidence of aGVHD, cGVHD, or rATG-F dose as the fac-
tors influencing relapse and mortality. Variables considered
in the model were those significant at a .20 level from the
univariable models. Variables remaining in the final models
were significant at a .05 level. Estimates for hazard ratios
(HRs) and corresponding 95% confidence intervals (CIs) were
obtained for each significant prognostic factor. All p values
are two sided. Statistical analysis was performed using SPSS
17.0 (SPSS Inc., Chicago, IL, USA), and p values based on
Gray’s test were estimated using NCSS version 11.0.9.ity from ClinicalKey.com by Elsevier on June 28, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
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The baseline patient-, disease-, and transplantation-related
characteristics are shown in Table 1. There was no signifi-
cant difference across the two groups in terms of patient
sex, age, risk of disease, type of disease, postinduction dis-
ease status, comorbidity, and transplantation risk.
When the patients were evaluated with regard to out-
come parameters, the median days of neutrophil engraft-
ment was 12.4 ± 1.6 (95% CI, 11.8–12.8) in Group 1
compared with 12.2 ± 0.5 (95% CI, 11.4–13.1) in Group 2
(p = .84; Table 2). The median days of platelet engraftment
was also similar in both groups (12.1 ± 1.1 vs. 12.3 ± 1.9; p =
.89; Table 2).
Although the mean OS was found to be 47 months and 17
months, the mean DFS was found to be 48 months and 14
months in Group 1 and Group 2, respectively. Univariate
analysis revealed the expected 1-year OS rates as 76.1%
and 86.9% for patients in Group 1 and Group 2, respectively
(p = .86; Table 2). The expected DFS was also similar
between the groups (76.1% vs. 82.6%; p = .86; Table 2).
Kaplan–Meier curve construction, followed by application
of the log-rank test, showed that neither OS nor DFS was
affected by the dose (p = .06 for OS and p = .11 for DFS;
Fig. 1).
Among recipients of Group I, the cumulative incidence of
NRM at 1 year was 4.3% compared with 4.3% in Group 2, and
NRM was found not to be influenced by rATG-F dose (p = .73;
Table 2; Fig. 2A). The cumulative incidence of relapse at 1
year was similar in Group 1 and Group 2 (13% vs. 13%; p =
.71; Table 2; Fig. 2B).Table 1 Baseline patient-, disease-, and transplantation-related
Variable Group 1 (N = 46)
Male, n (%) 21 (45.7)
Median age, y 40.3 ± 11.6
Risk of AML, n (%)
High 9 (19.6)
Intermediate 37 (80.4)
Type of AML, n (%)
Primary 39 (84.8)
AML with MRC 7 (11.6)
Molecular status, n (%)
MRD negative 16 (34.8)
MRD positive 22 (47.8)
No MRD assessment 8 (17.4)
Comorbidity score (Sorror), n (%)
High 10 (21.7)
Intermediate 18 (39.1)
Low 13 (28.3)
EBMT risk score  2, n (%) 34 (73.9)
Donor source was HLA-matched sibling in all transplants in both group
AML = acute myeloid leukemia; EBMT = European Group for Blood and
myelodysplasia-related change; MRD = minimal residual disease.
Downloaded for Anonymous User (n/a) at Baskent University
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and cGVHD, it was noted that whereas cumulative incidence
of aGVHD II–IV at 100 days was found to be 13.0% and 17.4%
(p = .51; Table 2), it was 8.7% and 0% for aGVHD III–IV in
Group 1 and Group 2, respectively (p = .20; Table 2). At
180 days, these values were 17.4% for the two groups for
aGVHD II–IV (p = .63; Table 2; Fig. 2A) and 8.7% versus 0%
for aGVHD III–IV in Group 1 and Group 2, respectively (p
= .20; Table 2; Fig. 2B).
Gray’s test revealed that the cumulative incidence of
cGVHD at 1 year was 58.7% and 34.8% in Group 1 and Group
2, respectively (p = .03; Table 2; Fig. 3C). At 1 year after
transplantation, the cumulative incidence of extensive
cGVHD was 23.9% in Group 1, whereas it was 34.8% in Group
2 (p = .36; Table 2; Fig. 3D).
Although immunosuppressive treatment could be discon-
tinued at 2 years after transplantation in 31 (75.6%) patients
in Group 1 and 17 (89.5%) patients in Group 2, there was no
statistically significant difference between the two groups
(p = .30; Table 2).
Infectious complications at 1 year increased in Group 2
(6.6% vs. 17.4%; p = .02; Table 2). Three (6.5%) patients in
Group 1 and two (8.6%) patients in Group 2 developed inva-
sive fungal infection, whereas 18 (39.1%) and six (26%)
patients developed CMV viremia, and six (13.0%) and three
(13.0%) patients developed herpes virus infection in Group
1 and Group 2, respectively. No patients developed rATG-
F-related severe adverse events (Common Terminology Cri-
teria grade 4 or 5).
A Cox regressionmodel including 69 AML patients revealed
that although aGVHD III–IV was associated with increased
NRM at 1 year (HR = 18.2; 95% CI, 1.667–199.255; p = <.02),characteristics.
Group 2 (N = 23) p
16 (69.6) .08
44.0 ± 11.1 .20
7 (30.4) .37
16 (69.6)
22 (95.7) .25
1 (4.3)
11 (47.8) .94
12 (52.1)
0
6 (26.1) .44
10 (43.9)
7 (30.4)
21 (91.3) .12
s.
Marrow Transplantation; HLA = human leukocyte antigen; MRC =
 from ClinicalKey.com by Elsevier on June 28, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Table 2 Transplant outcome.
Group 1 (N = 46) Group 2 (N = 23) p
Median days of N eng, d ± SD 12.4 ± 1.6 (95% CI, 11.8–12.8) 12.2 ± 0.5 (95% CI, 11.4–13.1) .85
Median days of P eng, d ± SD 12.1 ± 1.1 (95% CI, 11.4–12.8) 12.3 ± 1.9 (95% CI, 9.2–15.3) .89
OS, at 1 year, n (%)a 35 (82.2) 20 (78.7) .85
DFS, at 1 year, n (%)a 35 (75.8) 19 (82.6) .11
NRM, at 1 yearb 6.5% (95% CI, 2.4–10.8) 4.3% (95% CI, N/A) .73
Relapse at 1 yearb 17.7% (95% CI, 11.3–24.1) 13.1% (95% CI, 1.8–24.4) .71
aGVHD at 100 daysb
Grade II–IV 15.2% (95% CI, 9.2–21.2) 13% (95% CI, 1.7–24.3) .63
Grade III–IV 6.7% (95% CI, 2.5–10.9) 0 .20
aGVHD at 180 daysb
Grade II–IV 17.4% (95% CI, 11.0–23.8) 17.4% (95% CI, 4.7–30.1) .64
Grade III–IV 8.7% (95% CI, 3.0–13.4) 0 .20
cGVHD at 1 yearb
As a whole 7.3% (95% CI, 2.9–11.7) 11.1% (95% CI, 0.5–21.7) .03
Extensive 3.8% (95% CI, 0.6–7.1) 16.7% (95% CI, 4.2–29.2) .36
Cessation of IS at 2 years, n (%)c 31 (75.6) 17 (89.5) .30
Infection at 1 year, n (%)c 3 (6.5) 4 (17.4) .02
aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; CI = confidence interval; d = days; DFS = disease-free
survival; IS = immunosuppressives; N/A = nonavailable with NCSS system; N eng = neutrophil engraftment; NRM = nonrelapse mortality; OS
= overall survival; P eng = platelet engraftment; SD = standard deviation.
a Kaplan–Meier product limit estimate.
b Gray’s test cumulative incidence estimate.
c Chi-square test.
Effects of two doses of ATG-Fresenius 153it was not influenced by aGVHD II–IV (HR = 2.0; 95% CI,
0.260–16.801; p = .49), cGVHD (HR = 1.2; 95% CI, 0.446–
3.423; p = .68), or different rATG-F doses (HR = 1.1; 95% CI,
0.292–4.355; p = <.86; Table 3). By contrast, patients
showed no significant difference in the relapse risk following
aGVHD II–IV (HR = 1.1; 95% CI, 0.225–5.727; p = .88), aGVHD
III–IV (HR = 1.6; 95% CI, 0.137–20.195; p = .69), cGVHD (HR
= 1.9; 95% CI, 0.560–6.488; p = .30), or different rATG-F
doses (HR = 1.2; 95% CI, 0.314–4.756; p = .77; Table 4).
Discussion
Strong evidence indicates that antithymocyte globulin is
quite effective for prevention of cGVHD in unrelated allo-
geneic transplants [4,5,7,11], and the relapse rate is not
increased in the setting of myeloablative conditioning
[1,8]. Immunosuppressive treatment may be discontinued
early in many patients, except in those who were not in
complete remission prior to transplantation and who
received the reduced-intensity conditioning regimen. Fur-
thermore, infections did not increase in number, and quality
of life improved, unless given in high doses [8].
Many studies that were retrospective in nature and used
the reduced-intensity conditioning regimen have explored
the utility of thymoglobulin in patients receiving transplants
from HLA-matched sibling donors [17–21]. One study com-
pared the outcomes of patients who received transplants
from related and unrelated donors treated with the fludara-
bine/busulfan conditioning regimen [22]. The incidence of
cGVHD did not vary by donor type; however, the relapseDownloaded for Anonymous User (n/a) at Baskent Univers
For personal use only. No other uses without permissionrate was lower and DFS was longer when the donor was
unrelated [22]. A recently published study showed that
the use of Thymoglobulin with fludarabine/busulfan
myeloablative regimen followed by HLA-identical sibling
donor allogeneic HSCT for AML improves overall transplant
outcomes owing to the reduced incidence of cGVHD without
increased relapse risk, supporting our hypothesis [23].
The retrospective studies of Cornillon et al. [24] and
Salem et al. [25] explored the utility of low-dose Thy-
moglobulin. The first study compared the outcomes of
patients given two low doses (2.5 and 5 mg/kg); the latter
dose better protected against NRM. Furthermore, Salem
et al. [25] and Hamadani et al. [26] used fludarabine/busul-
fan conditioning and compared two doses (6 mg/kg and 7.5
mg/kg) [25,26]. No significant between-group difference
was evident in terms of cGVHD, and the latter reported
lower cytomegalovirus and bacterial infection rate. Mean-
while, Socie et al. [11] found that relapse risk did not
increase with thymoglobulin doses <6 mg/kg, and CIBMTR
data showed controversial results [19]. Thymoglobulin doses
of 10 mg/kg was found to lead to a poorer OS in a French
study [20]. Kanate et al. [27] have found that NRM and sur-
vival were not influenced by ATG use. By contrast, cGVHD
rates were better among the patients who received Thy-
moglobulin in their study, which investigated lymphoma
patients who underwent haplo transplant using cord blood.
The authors considered that prospective studies were
required to determine appropriate Thymoglobulin doses.
Despite the large number of studies investigating thy-
moglobulin, few studies have evaluated low-dose rATG-F.
The pharmacodynamics of thymoglobulin varies consider-ity from ClinicalKey.com by Elsevier on June 28, 2019.
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Fig. 1 Overall survival and disease-free survival according to
rATG-F dosage group. (A) Kaplan–Meier estimates of overall
survival following allogeneic transplantation. (B) Kaplan– Meier
estimates of disease-free survival following allogeneic trans-
plantation. Solid curves represent patients receiving rATG-F at
15 mg/kg (Group 1), whereas dashed curves represent patients
receiving the 30 mg/kg rATG-F dose (Group 2). rATG-F = anti-T
lymphocyte globulin Fresenius.
Fig. 2 (A) Cumulative incidence of nonrelapse mortality
according to the rATG-F dosage group. (B) Cumulative inci-
dence of disease relapse according to the ATG dosage group.
Solid curves represent patients receiving rATG-F at 15 mg/kg
(Group 1), whereas the dashed curves represent patients
receiving the 30 mg/kg rATG-F dose (Group 2). rATG-F = anti-
T lymphocyte globulin Fresenius.
154 C. Boga et al.ably. rATG-F is prepared from more homogenous cells than
is thymoglobulin. Placental cells must absorb higher con-
centrations of immunoglobulin G (IgG) antibodies (com-
pared to other antibodies) prior to cell lysis. The European
Group for Blood and Marrow Transplantation considers that
30 mg/kg of rATG-F is equivalent to 7.5 mg/kg of thy-
moglobulin when an unrelated transplant is contemplated
[1,28].
The prospective study of Kro¨ger et al. [29] is the most
recent work exploring the use of rATG-F in HLA-matched
sibling donors. The study found that the GVHD ratio was
lower, and GVHD-free and relapse-free survival were
longer, in an rATG-F versus non-rATG-F group. However,
all acute leukemia cases were included in the cited study,
and the conditioning regimens included cyclophosphamide,Downloaded for Anonymous User (n/a) at Baskent University
For personal use only. No other uses without permission. Ctotal body irradiation, or combination of busulfan and
etoposide. In their study, Ayuk et al. [30] compared 30
mg/kg versus 60 mg/kg rATG-F in patients who underwent
unrelated transplant. Although they found that acute and
chronic GVHD rates were similar, they noted that
transplant-related mortality and DFS were favorable in the
low-dose group. We earlier reported the outcomes of allo-
geneic transplant patients who received peripheral stem
cells from HLA-matched siblings, and who were given
rATG-F at 7.5–10 mg/kg as part of a busulfan/fludarabine
conditioning regimen [31]. Our results were found success-
ful at Years 1 and 3. However, it must be emphasized that
the study was retrospective in nature and we did not include
a control group.
We found that reduced-dose rATG-F yielded sufficient
outcomes in allogeneic stem cell transplant patients receiv-
ing cells from HLA-matched sibling donors. Recommended
dose rATG-F was found to reduce cumulative incidence of
cGVHD while leading to a mild increase in infection rates
without influencing transplant outcomes. A similar increase
in infection rate was observed with increasing dose of
Thymoglobulin. In the study of Ayuk et al. [30] reporting
that NRM is associated with infections, fatal infections
were detected in contrast to the findings of our study,
which revealed that NRM seems to be associated with
aGVHD III–IV. from ClinicalKey.com by Elsevier on June 28, 2019.
opyright ©2019. Elsevier Inc. All rights reserved.
Fig. 3 Cumulative incidence of GVHD according to the rATG-F dosage group. (A) cumulative incidence of grade II–IV aGVHD. (B)
Cumulative incidence of grade III–IV aGVHD. (C) Cumulative incidence of cGVHD as a whole. (D) Cumulative incidence of extensive
cGVHD. Solid curves represent patients receiving rATG-F at 15 mg/kg (Group 1), whereas dashed curves represent patients receiving
the 30 mg/kg rATG-F dose (Group 2). aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; rATG-F =
anti-T lymphocyte globulin Fresenius.
Table 3 Cox regression model for GVHD and rATG-F dose and the factors influencing NRM.
Analysis of maximum likelihood estimates
Parameter B Standard error Wald df p Hazard ratio 95% CI hazard ratio
Lower Upper
aGVHD II–IV .738 1.063 .482 1 .49 2.092 .260 16.801
aGVHD III–IV 2.903 1.220 5.659 1 .02 18.226 1.667 199.255
cGVHD .212 .520 .166 1 .68 1.236 .446 3.423
rATG-F dose .121 .689 .031 1 .86 1.128 .292 4.355
aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; B = beta (standardized regression coefficients); CI =
confidence interval; df = degree of freedom; rATG-F = rabbit anti-T lymphocyte globulin Fresenius.
Effects of two doses of ATG-Fresenius 155An advantage of low-dose rATG-F may lie in its effect on
natural cell counts. The T-suppressor effect persists for >1
year if rATG-F is used in addition to lympholytic medica-
tions. However, killer cell counts were reported to match
the prior levels if the dose was reduced [32,33]. Positive
correlations were evident between the natural killer cell
count, and DFS and OS, in transplant patients for whom
low-dose rATG-F had been added to the busulfan/fludara-
bine conditioning regimen (p = <.01 and p = .02, respec-
tively). Natural killer cell numbers >1.5  107/kg
correlated with a good prognosis [34].Downloaded for Anonymous User (n/a) at Baskent Univers
For personal use only. No other uses without permissionWe sought to investigate the effectiveness of different
doses of rATG-F. We studied homogenous patients undergo-
ing an identical busulfan/fludarabine conditioning regimen
and obtained peripheral stem cells using standardized oper-
ating procedures; these represent the strengths of our
study. The absence of a control group to which rATG-F
was not given may be a limitation of our study.
Dose difference of rATG-F did not influence survival
parameters; however, recommended dose seems to be
effective for reducing cGVHD with a slight increase in infec-
tion rate in AML patients who received myeloablative flu-ity from ClinicalKey.com by Elsevier on June 28, 2019.
. Copyright ©2019. Elsevier Inc. All rights reserved.
Table 4 Cox Regression Model for GVHD and rATG-F dose as the factors influencing relapse.
Analysis of maximum likelihood estimates
Parameter B Standard error Wald df p Hazard ratio 95% CI hazard ratio
Lower Upper
aGVHD II–IV .126 0.826 0.023 1 .88 1.134 0.225 5.727
aGVHD III–IV .508 1.274 0.159 1 .69 1.662 0.137 20.195
cGVHD .645 0.625 1.064 1 .30 1.906 0.560 6.488
rATG-F dose .201 0.693 0.084 1 .77 1.222 0.314 4.756
aGVHD = acute graft-versus-host disease; cGVHD = chronic graft-versus-host disease; B = beta (standardized regression coefficients); CI =
confidence interval; df = degree of freedom; rATG-F = rabbit anti-T lymphocyte globulin Fresenius.
156 C. Boga et al.darabine/busulfan conditioning. We may conclude that rec-
ommended dose rATG-F may be used effectively with care-
ful monitoring of infections.
In conclusion, reduced dose rATG-F seems sufficient to
reduce the incidence of cGVHD, and does not affect the
cumulative incidence of aGVHD without changing the out-
come in allogeneic transplant AML patients receiving cells
from HLA-matched donors subjected to fludarabine/busul-
fan conditioning regimes. Increasing the dose of r-ATG-F
to 30 mg/kg seems to be more effective for reducing cGVHD
with a slight increase in infection rate. Our results support
the notion that individualized rATG-F use and dose adjust-
ment could improve clinical outcomes. An increase in the
rate of infection suggests that close monitoring of infection
may be necessary. Prospective controlled randomized stud-
ies are required to draw any conclusive findings.
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